Alessandro Mannucci, MD, CGA-IGC Communications Committee Member Source: Hu H, Shen X, Li Y, et al. Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2026;27:1020–30. Why this trial matters Over the last five years, neoadjuvant PD-1 blockade has completely changed the management o
